Virology & Mycology
Open Access
ISSN: 2161-0517
ISSN: 2161-0517
Ssemuyiga Charles*, Mulumba Pius Edgar and Ndugwa Anthony Kasoma
Cases of the monkeypox virus have been recorded in non-endemic nations and have continued to be reported in several endemic nations since early May 2022. In this study, we modeled Monkeypox Virus (MPXV) Thymidylate Kinase (TMPK) and scaffolding protein (D13) and these models and their templates were taken for small molecule screening against 602,413 small molecules using pharmacophore modeling and molecular docking methods. Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) properties were also computed followed by Molecular simulation dynamics studies. All presented hits had superior molecular docking scores to used reference standards of Cidofovir and Rifampicin. TMPK compounds displayed better ADMET profiles than D13 compounds, hence the latter may necessitate ligand optimization. Following molecular dynamics simulation, analysis revealed that all generated complexes were stable, with the ligands NPC275538, NPC244454, 135566871 and CHEBI compounds outperforming other hits. These compounds still presented higher docking scores against cidofovir-resistant TMPK and Rifampicin-resistant D13 proteins. Compounds 447970, 446595 and 54723327 were most selective against human TMPK. The conserved interaction patterns of these compounds among vaccinia and monkeypox virus proteins with the fact that studied proteins are highly conserved across Orthopoxviruses (OPV) is appealing that these hits should be studied across OPV. Therefore, these compounds should be subjected to laboratory testing to prove their antipox capability. Since there are currently no approved MPXV antivirals, this discovery significantly aids in developing new drugs for treating monkeypox.
Published Date: 2023-11-02; Received Date: 2023-10-03